Nuvation's FDA decision on taletrectinib, a treatment for Non-small Cell Lung Cancer (NSCLC)
What the company said
“FDA had accepted a supplemental New Drug Application with updated data for IBTROZI in both TKI-naïve and TKI-pretreated advanced ROS1+ NSCLC with a target action date of January 4, 2027.”
More on NUVB and the FDA calendar
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Use this page
How to cite
Breakaway, Nuvation's FDA decision on taletrectinib, a treatment for Non-small Cell Lung Cancer (NSCLC), Nov 2, 2026, getbreakaway.com/biotech/NUVB-taletrectinib
Journalists: email support@getbreakaway.com for the data behind this page.